The results of this work have shown that tumor PD-L1 positivity (PD-L1 tumor cell staining ≥1%) is associated with significantly higher ORR, suggesting a potential role of tumor PD-L1 over-expression as predictive biomarker for clinical setting. The gene discussed is CD274; the disease is neoplasm.